Discovery of Potent STT3A/B Inhibitors and Assessment of Their Multipathogen Antiviral Potential and Safety

In the aftermath of the COVID-19 pandemic, opportunities to modulate biological pathways common to the lifecycles of viruses need to be carefully considered. <i>N</i>-linked glycosylation in humans is mediated exclusively by the oligosaccharyltransferase complex and is frequently hijacked by viruses to facilitate infection. As such, STT3A/B, the catalytic domain of the OST complex, became an intriguing drug target with broad-spectrum antiviral potential. However, due to the critical role <i>N</i>-linked glycosylation plays in a number of fundamental human processes, the toxicological ramifications of STT3A/B inhibition required attention commensurate to that given to antiviral efficacy. Herein, we describe how known STT3A/B inhibitor NGI-1 inspired the discovery of superior tool compounds which were evaluated in <i>in vitro</i> efficacy and translational safety (e.g., CNS, cardiovascular, liver) studies. The described learnings will appeal to those interested in the therapeutic utility of modulating <i>N</i>-linked glycosylation as well as the broader scientific community.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2024-08-13
DOI
https://doi.org/10.1021/acs.jmedchem.4c01402
Citations
7
Primary Topic
RNA and protein synthesis mechanisms
Type
article
Field-Weighted Citation Impact
1.64

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of Potent STT3A/B Inhibitors and Assessment of Their Multipathogen Antiviral Potential and Safety

Jiayi Zhou, Malar Pannirselvam, Joseph E. Pero, Michael R. McAllaster et al.
7 citations
Journal of Medicinal Chemistry
RNA and protein synthesis mechanisms
1.64
article

Discovery of Potent STT3A/B Inhibitors and Assessment of Their Multipathogen Antiviral Potential and Safety

Jiayi Zhou, Malar Pannirselvam, Joseph E. Pero, Michael R. McAllaster, Ona Barauskas, Charles F. McHugh, Ashley M. Adams, Christophe Colas, Johannes Grosse, Deidre A. Dalmas, Lindsey Talecki, Andrew J. Peat, Maria Concetta Nigro, Beth Fernandez, Elizabeth A. Mueller, Earl Gordon, Fatai S. Oladunni, Haiying Cai, Dale R. Balce, Thilo Werner, Laura Wedel, Neil D. Pearson, Ramona S. Adolph, Belinda E. Hetzler, H. Christian Eberl, Rohit Ranjan, Neil R. Stokes, Matthew J. Cato, Marcus Bantscheff, Leah Soriaga, Amalio Telenti, Yi-Pei Chen, István Bartha, Dana Bohan, Arnold Park, Parikshit Bagchi, Zachary E. Newby, Seungmin Hwang, Pegah Safabakhsh, Winston C. Tse, Samantha S. Yim, Khuram W. Chaudhary, David Sweeney, Corey Momont, Shuya Wang, Lisha Wang, Sam Jeyasingh, Bob Plastridge, Isra Darwech, B. Kowalski, Dingjun Chen, James T. Cassidy, Stephanie Lehmann, J oslash rgen Fischer Hansen, Esteban Carabajal, G.F. Lo, A. Terrell, Nathan D. Shapiro
article en
7 citations

Abstract

In the aftermath of the COVID-19 pandemic, opportunities to modulate biological pathways common to the lifecycles of viruses need to be carefully considered. <i>N</i>-linked glycosylation in humans is mediated exclusively by the oligosaccharyltransferase complex and is frequently hijacked by viruses to facilitate infection. As such, STT3A/B, the catalytic domain of the OST complex, became an intriguing drug target with broad-spectrum antiviral potential. However, due to the critical role <i>N</i>-linked glycosylation plays in a number of fundamental human processes, the toxicological ramifications of STT3A/B inhibition required attention commensurate to that given to antiviral efficacy. Herein, we describe how known STT3A/B inhibitor NGI-1 inspired the discovery of superior tool compounds which were evaluated in <i>in vitro</i> efficacy and translational safety (e.g., CNS, cardiovascular, liver) studies. The described learnings will appeal to those interested in the therapeutic utility of modulating <i>N</i>-linked glycosylation as well as the broader scientific community.

Journal of Medicinal ChemistryVol. 67(16)
South College (US), VIR Biotechnology (United States) (US)
GlaxoSmithKline, Vir Biotechnology
Openalex Percentile: Top 16%
RNA and protein synthesis mechanisms
1.64
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.